Jazz Pharmaceuticals (JAZZ) EPS (Weighted Average and Diluted) (2010 - 2026)

Jazz Pharmaceuticals' EPS (Weighted Average and Diluted) history runs 17 years deep, the most recent figure standing at $4.43 for Q1 2026.

• In Q1 2026, EPS (Weighted Average and Diluted) rose 391.45% year-over-year to $4.43; the TTM figure through Mar 2026 stood at $0.11 (down 98.52% YoY), while the FY2025 annual figure was -$5.84, down 167.51% from the prior year.
• EPS (Weighted Average and Diluted) was $4.43 for Q1 2026 at Jazz Pharmaceuticals, up from $3.34 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $4.43 in Q1 2026 to a low of -$11.74 in Q2 2025.
• Historically, EPS (Weighted Average and Diluted) has averaged $0.58 across 5 years, with a median of $1.43 in 2023.
• The sharpest annual moves came in 2022 and 2023: EPS (Weighted Average and Diluted) slumped 611.11% in 2022, then surged 3366.67% in 2023.
• A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$3.84 in 2022, then surged by 137.24% to $1.43 in 2023, then soared by 111.19% to $3.02 in 2024, then gained by 10.6% to $3.34 in 2025, then jumped by 32.63% to $4.43 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $4.43 (Q1 2026), $3.34 (Q4 2025), and $4.08 (Q3 2025), per Business Quant data.